In a regulatory filing, Royalty Pharma disclosed that its director Rory Riggs sold 470K shares of common stock on January 2nd as part of option exercise in a total transaction size of $13.2M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RPRX:
- Royalty Pharma price target lowered by $11 at Morgan Stanley, here’s why
- Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
- Royalty Pharma to fund up to $125M for LAI Program in collaboration with Teva
- Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
- Royalty Pharma Q3 revenue $536M, consensus $614.36M
